{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:21:48Z","timestamp":1787772108372,"version":"build-2784847793"},"reference-count":71,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Bile acids serve as endogenous ligands for nuclear and cell membrane receptors and play a crucial role in bile acid and lipid metabolism. These detergent-like compounds promote bile flow and aid in the absorption of dietary fats and fat-soluble vitamins in the intestine. Synthesized in the liver as end products of cholesterol catabolism, bile acids exhibit a chemical structure comprising a nucleus and a side chain featuring a carboxyl group, with diverse steric arrangements and potential polar substituents. Critical interactions occur between bile acid species and various nuclear and cell membrane receptors, including the farnesoid X receptor and G-protein\u2013coupled bile acid receptor 1. This research aimed to review the literature on bile acids and their roles in treating different diseases. Currently, numerous investigations are concentrating on specific bile acid species that target nuclear receptors in the gastrointestinal system, aiming to improve the treatment of conditions such as nonalcoholic fatty liver disease. Given the global attention this topic has garnered from research groups, it is considered relatively new, thus anticipating some gaps or incomplete data. Bile acid species have a significant therapeutic promise, especially in their ability to activate or inhibit nuclear receptors, such as farnesoid X receptor. This research provides to offer essential information for scientists and medical practitioners interested in discovering new studies that underscore the importance of bile acids in ameliorating and impeding the progression of disorders. Furthermore, it opens avenues for previously overlooked bile acid\u2013based therapies.<\/jats:p>","DOI":"10.4103\/sjg.sjg_53_24","type":"journal-article","created":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T08:00:10Z","timestamp":1714982410000},"page":"283-293","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Unravelling the therapeutic landscape of bile acid-based therapies in gastrointestinal disorders"],"prefix":"10.4103","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6224-0198","authenticated-orcid":false,"given":"Bandar D.","family":"Alrehaili","sequence":"first","affiliation":[{"name":"Pharmacology and Toxicology Department, Pharmacy College, Taibah University, Medina, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,5,6]]},"reference":[{"key":"R1-20240913","doi-asserted-by":"crossref","first-page":"754067","DOI":"10.1155\/2012\/754067","article-title":"Bile acid signaling in liver metabolism and diseases","volume":"2012","author":"Li","year":"2012","journal-title":"J Lipids"},{"key":"R2-20240913","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1194\/jlr.M071183","article-title":"Cyp2c70 is responsible for the species difference in bile acid metabolism between mice and humans","volume":"57","author":"Takahashi","year":"2016","journal-title":"J Lipid Res"},{"key":"R3-20240913","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1194\/jlr.C120000621","article-title":"Is CYP2C70 the key to new mouse models to understand bile acids in humans?","volume":"61","author":"Guo","year":"2020","journal-title":"J Lipid Res"},{"key":"R4-20240913","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1146\/annurev-nutr-082018-124344","article-title":"Bile acids as metabolic regulators and nutrient sensors","volume":"39","author":"Chiang","year":"2019","journal-title":"Annu Rev Nutr"},{"key":"R6-20240913","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0016-5085(78)93767-8","article-title":"Hepatic taurine concentration and dietary taurine as regulators of bile acid conjugation with taurine","volume":"75","author":"Hardison","year":"1978","journal-title":"Gastroenterology"},{"key":"R7-20240913","doi-asserted-by":"crossref","first-page":"19375","DOI":"10.1016\/S0021-9258(17)32178-6","article-title":"Glycine and taurine conjugation of bile acids by a single enzyme. Molecular cloning and expression of human liver bile acid CoA: Amino acid N-acyltransferase","volume":"269","author":"Falany","year":"1994","journal-title":"J Biol Chem"},{"key":"R8-20240913","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/S0022-2275(20)37196-0","article-title":"Cloning, expression, and chromosomal localization of mouse liver bile acid CoA: amino acid N-acyltransferase","volume":"38","author":"Falany","year":"1997","journal-title":"J Lipid Res"},{"key":"R9-20240913","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.3390\/nu11061356","article-title":"Glycine metabolism and its alterations in obesity and metabolic diseases","volume":"11","author":"Alves","year":"2019","journal-title":"Nutrients"},{"key":"R10-20240913","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00726-012-1381-0","article-title":"Taurine and liver diseases:A focus on the heterogeneous protective properties of taurine","volume":"46","author":"Miyazaki","year":"2014","journal-title":"Amino Acids"},{"key":"R11-20240913","doi-asserted-by":"crossref","first-page":"257","DOI":"10.4093\/dmj.2019.0043","article-title":"Understanding bile acid signaling in diabetes:From pathophysiology to therapeutic targets","volume":"43","author":"Ferrell","year":"2019","journal-title":"Diabetes Metab J"},{"key":"R12-20240913","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1194\/jlr.M500178-JLR200","article-title":"A phylogenetic survey of biliary lipids in vertebrates","volume":"46","author":"Moschetta","year":"2005","journal-title":"J Lipid Res"},{"key":"R13-20240913","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1194\/jlr.R000042","article-title":"Bile salts of vertebrates:Structural variation and possible evolutionary significance","volume":"51","author":"Hofmann","year":"2010","journal-title":"J Lipid Res"},{"key":"R14-20240913","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1093\/toxsci\/kfn268","article-title":"Bile Acid sulfation:A pathway of bile acid elimination and detoxification","volume":"108","author":"Alnouti","year":"2009","journal-title":"Toxicol Sci"},{"key":"R15-20240913","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/cphy.c120023","article-title":"Bile acid metabolism and signaling","volume":"3","author":"Chiang","year":"2013","journal-title":"Compr Physiol"},{"key":"R16-20240913","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1053\/j.gastro.2006.02.012","article-title":"Mice deleted for fatty acid transport protein 5 have defective bile acid conjugation and are protected from obesity","volume":"130","author":"Hubbard","year":"2006","journal-title":"Gastroenterology"},{"key":"R17-20240913","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s10545-011-9416-3","article-title":"Bile acid-CoA ligase deficiency--a new inborn error of bile acid metabolism","volume":"35","author":"Chong","year":"2012","journal-title":"J Inherit Metab Dis"},{"key":"R18-20240913","doi-asserted-by":"crossref","first-page":"10046","DOI":"10.1074\/jbc.273.16.10046","article-title":"The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver","volume":"273","author":"Gerloff","year":"1998","journal-title":"J Biol Chem"},{"key":"R19-20240913","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jhep.2012.08.002","article-title":"Bile acid transporters and regulatory nuclear receptors in the liver and beyond","volume":"58","author":"Halilbasic","year":"2013","journal-title":"J Hepatol"},{"key":"R20-20240913","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1002\/hep4.2041","article-title":"Bile acid conjugation deficiency causes hypercholanemia, hyperphagia, islet dysfunction, and gut dysbiosis in mice","volume":"6","author":"Alrehaili","year":"2022","journal-title":"Hepatol Commun"},{"key":"R21-20240913","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/apt.17362","article-title":"Secondary bile acids improve risk prediction for non-invasive identification of mild liver fibrosis in nonalcoholic fatty liver disease","volume":"57","author":"Liu","year":"2023","journal-title":"Aliment Pharmacology Ther"},{"key":"R22-20240913","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13578-023-01035-1","article-title":"Bile acid-mediated signaling in cholestatic liver diseases","volume":"13","author":"Zeng","year":"2023","journal-title":"Cell Biosci"},{"key":"R23-20240913","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1007\/s11739-023-03343-3","article-title":"The interaction of bile acids and gut inflammation influences the pathogenesis of inflammatory bowel disease","volume":"18","author":"Di Ciaula","year":"2023","journal-title":"Intern Emerg Med"},{"key":"R24-20240913","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0140-6736(88)92359-8","article-title":"Defective bile acid amidation:Predicted features of a new inborn error of metabolism","volume":"2","author":"Hofmann","year":"1988","journal-title":"Lancet"},{"key":"R25-20240913","doi-asserted-by":"crossref","first-page":"433","DOI":"10.4254\/wjh.v13.i4.433","article-title":"Bile acid indices as biomarkers for liver diseases I: Diagnostic markers","volume":"13","author":"Alamoudi","year":"2021","journal-title":"World J Hepatol"},{"key":"R26-20240913","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3389\/fmed.2020.00015","article-title":"Bile acid receptor therapeutics effects on chronic liver diseases","volume":"7","author":"Meadows","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"R27-20240913","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1007\/s10620-015-3776-8","article-title":"Altered bile acid metabolome in patients with nonalcoholic steatohepatitis","volume":"60","author":"Ferslew","year":"2015","journal-title":"Dig Dis Sci"},{"key":"R28-20240913","doi-asserted-by":"crossref","first-page":"e0151829","DOI":"10.1371\/journal.pone.0151829","article-title":"Bile acids and dysbiosis in non-alcoholic fatty liver disease","volume":"11","author":"Mouzaki","year":"2016","journal-title":"PLoS One"},{"key":"R29-20240913","doi-asserted-by":"crossref","first-page":"543","DOI":"10.4254\/wjh.v13.i5.543","article-title":"Bile acid indices as biomarkers for liver diseases II:The bile acid score survival prognostic model","volume":"13","author":"Alamoudi","year":"2021","journal-title":"World J Hepatol"},{"key":"R30-20240913","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.3389\/fimmu.2018.01853","article-title":"Bile acids activated receptors regulate innate immunity","volume":"9","author":"Fiorucci","year":"2018","journal-title":"Front Immunol"},{"issue":"(Suppl 1)","key":"R31-20240913","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S2210-7401(12)70015-3","article-title":"Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases:An overview of their mechanisms of action","volume":"36","author":"Poupon","year":"2012","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"R32-20240913","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/ncpgasthep0521","article-title":"Drug insight:Mechanisms and sites of action of ursodeoxycholic acid in cholestasis","volume":"3","author":"Beuers","year":"2006","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"key":"R33-20240913","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jhep.2017.05.009","article-title":"norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis","volume":"67","author":"Fickert","year":"2017","journal-title":"J Hepatol"},{"key":"R34-20240913","doi-asserted-by":"crossref","first-page":"557","DOI":"10.17235\/reed.2018.5533\/2018","article-title":"Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA","volume":"110","author":"Duan","year":"2018","journal-title":"Rev Esp Enferm Dig"},{"key":"R35-20240913","doi-asserted-by":"crossref","first-page":"152","DOI":"10.21037\/hbsn.2019.09.03","article-title":"Bile acid-based therapies for non-alcoholic steatohepatitis and alcoholic liver disease","volume":"9","author":"Li","year":"2020","journal-title":"Hepatobiliary Surg Nutr"},{"key":"R36-20240913","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3390\/ph11040104","article-title":"Obeticholic acid:A new era in the treatment of nonalcoholic fatty liver disease","volume":"11","author":"Abenavoli","year":"2018","journal-title":"Pharmaceuticals"},{"key":"R37-20240913","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1111\/liv.14490","article-title":"A novel non-bile acid FXR agonist EDP-305 potently suppresses liver injury and fibrosis without worsening of ductular reaction","volume":"40","author":"An","year":"2020","journal-title":"Liver Int"},{"key":"R38-20240913","doi-asserted-by":"crossref","first-page":"4","DOI":"10.11648\/j.ijg.20190301.12","article-title":"Characterization of EDP-305, a highly potent and selective farnesoid X receptor agonist, for the treatment of non-alcoholic steatohepatitis","volume":"3","author":"Chau","year":"2019","journal-title":"Int J Gastroenterol"},{"key":"R39-20240913","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/j.dld.2019.12.129","article-title":"Tropifexor, a highly potent FXR agonist, produces robust and dose-dependent reductions in hepatic fat and serum alanine aminotransferase in patients with fibrotic NASH after 12 weeks of therapy:FLIGHT-FXR Part C interim results","volume":"52","author":"Lucas","year":"2020","journal-title":"Dig Liver Dis"},{"key":"R40-20240913","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41591-022-02200-8","article-title":"Tropifexor for nonalcoholic steatohepatitis:An adaptive, randomized, placebo-controlled phase 2a\/b trial","volume":"29","author":"Sanyal","year":"2023","journal-title":"Nat Med"},{"key":"R41-20240913","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3390\/biomedicines9010060","article-title":"The non-steroidal FXR agonist cilofexor improves portal hypertension and reduces hepatic fibrosis in a rat NASH model","volume":"9","author":"Schwabl","year":"2021","journal-title":"Biomedicines"},{"key":"R42-20240913","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1021\/acs.jmedchem.9b01621","article-title":"Nidufexor (LMB763), a novel fxr modulator for the treatment of nonalcoholic steatohepatitis","volume":"63","author":"Chianelli","year":"2020","journal-title":"J Med Chem"},{"key":"R43-20240913","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"R44-20240913","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1053\/j.gastro.2013.05.042","article-title":"Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease","volume":"145","author":"Mudaliar","year":"2013","journal-title":"Gastroenterology"},{"key":"R45-20240913","doi-asserted-by":"crossref","first-page":"9039","DOI":"10.3748\/wjg.v22.i41.9039","article-title":"Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease","volume":"22","author":"Makri","year":"2016","journal-title":"World J Gastroenterol"},{"key":"R46-20240913","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.cgh.2019.09.050","article-title":"Long-term obeticholic acid therapy improves histological endpoints in patients with primary biliary cholangitis","volume":"18","author":"Bowlus","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R47-20240913","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1053\/j.gastro.2016.08.057","article-title":"An intestinal microbiota-farnesoidxreceptor axis modulates metabolic disease","volume":"151","author":"Gonzalez","year":"2016","journal-title":"Gastroenterology"},{"key":"R48-20240913","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1038\/s41591-018-0222-4","article-title":"Gut microbiota and intestinal FXR mediate the clinical benefits of metformin","volume":"24","author":"Sun","year":"2018","journal-title":"Nat Med"},{"key":"R49-20240913","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1111\/bph.12426","article-title":"GPBA: A GPCR for bile acids and an emerging therapeutic target for disorders of digestion and sensation","volume":"171","author":"Lieu","year":"2014","journal-title":"Br J Pharmacol"},{"key":"R50-20240913","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.dld.2013.10.021","article-title":"The bile acid TGR5 membrane receptor: From basic research to clinical application","volume":"46","author":"Duboc","year":"2014","journal-title":"Dig Liver Dis"},{"key":"R51-20240913","doi-asserted-by":"crossref","first-page":"G554","DOI":"10.1152\/ajpgi.00223.2019","article-title":"Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy","volume":"318","author":"Chiang JY Ferrell","year":"2020","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"R52-20240913","doi-asserted-by":"crossref","first-page":"11203","DOI":"10.1038\/s41598-017-11549-7","article-title":"Long-term administration of nuclear bile acid receptor FXR agonist prevents spontaneous hepatocarcinogenesis in Abcb4(-\/-) mice","volume":"7","author":"Cariello","year":"2017","journal-title":"Sci Rep"},{"key":"R53-20240913","doi-asserted-by":"crossref","first-page":"42801","DOI":"10.1038\/srep42801","article-title":"BAR502, a dual FXR and GPBAR1 agonist, promotes browning of white adipose tissue and reverses liver steatosis and fibrosis","volume":"7","author":"Carino","year":"2017","journal-title":"Sci Rep"},{"key":"R54-20240913","doi-asserted-by":"crossref","first-page":"9196","DOI":"10.1038\/s41598-021-88493-0","article-title":"Discovery, optimization, and evaluation of non-bile acid FXR\/TGR5 dual agonists","volume":"11","author":"Miyata","year":"2021","journal-title":"Sci Rep"},{"key":"R55-20240913","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1002\/hep.28991","article-title":"New therapeutic concepts in bile acid transport and signaling for management of cholestasis","volume":"65","author":"Trauner","year":"2017","journal-title":"Hepatology"},{"key":"R56-20240913","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/nmo.12370","article-title":"The role of bile acids in functional GI disorders","volume":"26","author":"Appleby","year":"2014","journal-title":"Neurogastroenterol Motil"},{"key":"R57-20240913","doi-asserted-by":"crossref","first-page":"416","DOI":"10.7326\/0003-4819-121-6-199409150-00004","article-title":"Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial","volume":"121","author":"Garg","year":"1994","journal-title":"Ann Intern Med"},{"key":"R58-20240913","doi-asserted-by":"crossref","first-page":"G371","DOI":"10.1152\/ajpgi.00400.2012","article-title":"Colesevelam suppresses hepatic glycogenolysis by TGR5-mediated induction of GLP-1 action in DIO mice","volume":"304","author":"Potthoff","year":"2013","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"R59-20240913","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.jcmgh.2021.04.013","article-title":"Combined ASBT inhibitor and FGF15 treatment improves therapeutic efficacy in experimental nonalcoholic steatohepatitis","volume":"12","author":"Matye","year":"2021","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"R60-20240913","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","article-title":"Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid","volume":"148","author":"Hirschfield","year":"2015","journal-title":"Gastroenterology"},{"key":"R61-20240913","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/cpdd.762","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel non-bile acid FXR agonist tropifexor (LJN452) in healthy volunteers","volume":"9","author":"Badman","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"key":"R62-20240913","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/hep.30509","article-title":"The nonsteroidal farnesoidxreceptor agonist cilofexor (GS-|y9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis","volume":"70","author":"Trauner","year":"2019","journal-title":"Hepatology"},{"key":"R63-20240913","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/hep.31205","article-title":"Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH:A phase 2 randomized controlled trial","volume":"72","author":"Patel","year":"2020","journal-title":"Hepatology"},{"key":"R64-20240913","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nm.3760","article-title":"Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance","volume":"21","author":"Fang","year":"2015","journal-title":"Nat Med"},{"key":"R65-20240913","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2165\/00003495-198019030-00001","article-title":"Colestipol: A review of its pharmacological properties and therapeutic efficacy in patients with hypercholesterolaemia","volume":"19","author":"Heel","year":"1980","journal-title":"Drugs"},{"key":"R66-20240913","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1001\/archinte.168.14.1531","article-title":"Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy","volume":"168","author":"Goldberg","year":"2008","journal-title":"Arch Intern Med"},{"key":"R67-20240913","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2165\/00003495-200868010-00006","article-title":"Sevelamer hydrochloride:A review of its use for hyperphosphataemia in patients with end-stage renal disease on haemodialysis","volume":"68","author":"Goldsmith","year":"2008","journal-title":"Drugs"},{"key":"R68-20240913","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/j.1872-034X.2009.00507.x","article-title":"Treatment of nonalcoholic steatohepatitis with colestimide","volume":"39","author":"Taniai","year":"2009","journal-title":"Hepatol Res"},{"key":"R69-20240913","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/S0140-6736(17)30319-7","article-title":"Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis:A double-blind, randomised, placebo-controlled, crossover, phase 2a study","volume":"389","author":"Hegade","year":"2017","journal-title":"Lancet"},{"key":"R70-20240913","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1038\/s41598-018-25214-0","article-title":"Pilot study with IBAT inhibitor A4250 for the treatment of cholestatic pruritus in primary biliary cholangitis","volume":"8","author":"Al-Dury","year":"2018","journal-title":"Sci Rep"},{"key":"R71-20240913","first-page":"537","article-title":"Safety and efficacy of elobixibat for chronic constipation:Results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial","volume":"20183","author":"Nakajima","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R72-20240913","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1053\/j.gastro.2020.08.004","article-title":"Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis","volume":"160","author":"Harrison","year":"2021","journal-title":"Gastroenterology"}],"container-title":["Saudi Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/sjg.sjg_53_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:30:22Z","timestamp":1787769022000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/sjg.sjg_53_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,6]]},"references-count":71,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/sjg.sjg_53_24","relation":{},"ISSN":["1319-3767","1998-4049"],"issn-type":[{"value":"1319-3767","type":"print"},{"value":"1998-4049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,6]]},"assertion":[{"value":"2024-02-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-05","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}